Chigasaki, Japan

Masahiro Sakaitani



 

Average Co-Inventor Count = 9.8

ph-index = 3

Forward Citations = 279(Granted Patents)


Location History:

  • Chigasaki, JP (2002 - 2008)
  • Shizuoka, JP (2011)
  • Kamakura, JP (2011 - 2013)
  • Hokkaido, JP (2018)

Company Filing History:


Years Active: 2002-2018

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Masahiro Sakaitani: Innovator in Pharmaceutical Chemistry

Introduction

Masahiro Sakaitani is a prominent inventor based in Chigasaki, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 11 patents. His work focuses on developing innovative compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents, Sakaitani has developed quinazolinone and isoquinolinone derivatives. These compounds are represented by a specific formula and include pharmaceutically acceptable salts. Another notable invention is a p27 protein inducer, which comprises a compound represented by a general formula as an active ingredient. This invention aims to provide a new approach to inducing p27 protein, which plays a crucial role in cell cycle regulation.

Career Highlights

Sakaitani has worked with several reputable companies throughout his career. Notably, he has been associated with Chugai Pharmaceutical Co., Ltd. and Basilea Pharmaceutica AG. His experience in these organizations has allowed him to advance his research and contribute to the development of new pharmaceutical products.

Collaborations

Sakaitani has collaborated with notable colleagues in his field, including Eisaku Mizuguchi and Nobuo Shimma. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work.

Conclusion

Masahiro Sakaitani is a distinguished inventor whose contributions to pharmaceutical chemistry are noteworthy. His innovative patents and collaborations reflect his commitment to advancing medical science. His work continues to influence the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…